[1]
|
Tan WJ, Zhao X, Ma XJ, Wang WL, Niu PH, Xu WB, et al. A novel coronavirus genome identified in a cluster of pneumonia cases—Wuhan, China 2019−2020. China CDC Wkly 2020;2(4):61 − 2. http://dx.doi.org/10.46234/ccdcw2020.017CrossRef
|
[2]
|
Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID’s innovative contribution to global health. Glob Chall 2017;1(1):33 − 46. http://dx.doi.org/10.1002/GCH2.1018CrossRef
|
[3]
|
Shu YL, McCauley J. GISAID: global initiative on sharing all influenza data–from vision to reality. Eurosurveillance 2017;22(13):30494. http://dx.doi.org/10.2807/1560-7917.ES.2017.22.13.30494CrossRef
|
[4]
|
Swaminathan S. The WHO's chief scientist on a year of loss and learning. Nature 2020;588(7839):583 − 5. http://dx.doi.org/10.1038/d41586-020-03556-yCrossRef
|
[5]
|
Bohn MK, Mancini N, Loh TP, Wang CB, Grimmler M, Gramegna M, et al. IFCC interim guidelines on molecular testing of SARS-CoV-2 infection. Clin Chem Lab Med 2020;58(12):1993 − 2000. http://dx.doi.org/10.1515/cclm-2020-1412CrossRef
|
[6]
|
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med 2020;383(27):2603 − 15. http://dx.doi.org/10.1056/NEJMoa2034577CrossRef
|
[7]
|
GISAID. EpiCoV Data Curation Team. 2021. https://www.gisaid.org/about-us/acknowledgements/data-curation/. [2021-10-21].https://www.gisaid.org/about-us/acknowledgements/data-curation/ |